David Sallman, MD

Articles by David Sallman, MD

At SOHO 2026, David Sallman, MD, explained why ofirnoflast produced responses across MDS subtypes, including in a patient with TP53-mutant disease.

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

ByDavid Sallman, MD

September 11th 2026

At SOHO 2026, David Sallman, MD, explained why ofirnoflast produced responses across MDS subtypes, including in a patient with TP53-mutant disease.

Latest Updated Articles

Trending on CancerNetwork

EPCORE FL-1 Shows Efficacy and Safety of Epcoritamab Combination Therapy

Novel Agents Reshape Sequencing Across Different Lymphoma Populations

What Faster Pharmacokinetics Mean for Detecting Small Brain Metastases

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

Participating Faculty: Antibody-Drug Conjugates in Advanced/Metastatic Non–Small Cell Lung Cancer